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Objective: To compare health outcomes during 14 year observational follow-up in women initially randomised to unopposed estrogen or placebo. 
Design: At recruitment to the Estrogen for the Prevention of Re-Infarction Trial (ESPRIT) women were assigned to estradiol valerate: 2mg or placebo treatment for 2 years. 
Setting. Women were recruited from 35 hospitals in the north west of England and Wales in July 1996-February 2000.
Sample. Women aged 50-69 surviving their first myocardial infarction
 Methods: All women were followed by data linkage to UK mortality and cancer records; mean follow-up 14.1 and 12.6 years respectively. In an intention to treat analysis Hazard Ratios (HRs) were computed, overall and stratified by age at recruitment. 
Outcome measures: Death (all cause, cardiac disease, stroke or cancer) and cancer incidence (any, breast or endometrium).
Results:  There were 418 deaths in 1017 women randomised.  The all-cause mortality Hazards Ratio of 1.07 (95%CI 0.88-1.29) indicated no significant difference between treatment groups.  Women aged 50-59 years at recruitment had lower HRs than women aged 60-69 years for all outcomes except ischemic heart disease. Amongst 149 incident cancers there were 7 cases of breast cancer in the intervention arm and 15 in the placebo; HR 0.47 (95%CI 0.19-1.15). There were no deaths from endometrial cancer but 3 incident cases, 1 in the active arm and 2 in placebo.
Conclusions:  These results suggest that unopposed oestrogen may be safely used for a short duration by women surviving a first myocardial infarction. 







The ESPRIT trial [1] was designed to investigate whether estrogen (estradiol valerate) reduced the risk of re-infarction, cardiac death or all cause mortality in postmenopausal women recruited at the time of hospital admission for a first myocardial infarction (MI). Few other trials of the health effects of hormone replacement therapy (HRT) have used estrogen without progesterone (unopposed estrogen) in women with an intact uterus.  The recent Cochrane review [2] lists only two (EPAT [3] and PEPI [4]), both of which used surrogate markers of disease rather than clinical outcomes. The largest trial of unopposed estrogen (Women’s Health Initiative Estrogen-Alone Trial (WHI E-A)[5]),  which recruited women in good health, initially included women with an intact uterus in the unopposed estrogen  arm but later changed the protocol because of concerns about endometrial hyperplasia [6]. The ESPRIT trial used estrogen without progesterone for all women in the treatment arm, including those with an intact uterus, because of concern about the safety of using progesterone in women with recent MI. The follow-up described in this report was planned primarily to determine whether this use of unopposed estrogen was detrimental, specifically whether there was any evidence of excess endometrial cancer that might be attributed to the intervention.  
Recently published data from the WHI E-A trial has demonstrated a protective effect of unopposed conjugated equine estrogens (CEE) on invasive breast cancer in women of all ages in that trial and, in younger women (aged 50-59 years at enrolment), on incidence of coronary heart disease (CHD), MI and death (all causes), with a trend towards more adverse outcomes in those over 60 years [7]. Although smaller than WHI E-A, ESPRIT, with 1017 subjects randomized, is larger than any other trial using unopposed oestrogen. Continued follow-up of the women recruited provided the opportunity to assess whether the WHI-E-A results on incident breast cancer and death from all causes, stratified by age, were found also in women recruited in a different country and exposed to a different type of estrogen (estadiol valerate rather than CEE used in the WHI E-A). 

Methods
As described in the earlier report [1], 1017 women age 50-69 years who had survived a first MI were recruited at the time of their hospitalization for MI from 35 collaborating hospitals in the north west of England and Wales between July 1996 and February 2000. Women who reported a history of cancer or use of hormone replacement therapy in the previous 12 months were excluded. Subjects were randomized to receive either one tablet of estradiol valerate (2mg; n=513) or placebo (n=504), daily for 2 years. Each subject was followed up through their family physician at 3, 6, 12, 18 and 24 months from date of recruitment, with follow-up of the last recruit ending on February 2nd 2002. The outcome of this initial ‘active’ follow-up has been reported previously [1].  

Given the unconventional use of unopposed estrogen in women with an intact uterus (373/513 in the active treatment arm), strict trial procedures sought to maximise the notification of all episodes of vaginal bleeding, and provide effective management of such episodes [1]. Women with vaginal bleeding during the trial were clinically assessed and, if appropriate, had a pipelle endometrial biopsy followed by a 14 day course of medroxyprogesterone acetate 20mg, increased to 3 courses each lasting 14 days if the biopsy showed complex hyperplasia.  When women with an intact uterus stopped active or placebo treatment, at two years after study entry or earlier, those who had not previously been investigated for vaginal bleeding were offered an endometrial biopsy. Women in the active arm who had not had a hysterectomy were also sent a letter each year for 5 years after stopping treatment to remind them to seek medical attention if they experienced vaginal bleeding. There was no attempt after the end of the 2 year intervention period to obtain information from women or their physicians about medication (including use of estrogen) or health events. However, all 1017 women were flagged at recruitment on the UK National Health Service central register so that deaths and cancers could be notified through record linkage. The analyses reported here are based on these notifications.
Follow-up for this paper was to 31st December 2010 for cancer incidence (mean follow-up 12.6 years range 10.9-14.5) and to 30 June 2012 for mortality (mean follow-up 14.1 years range 12.4-16.0). Cancer incidence, vital status and cause of death were determined from data routinely collected by the Office of National Statistics for England and Wales, and by parallel systems in Scotland for women who had moved there after recruitment into the study. Cancer incidence data are routinely collected by regional cancer boards and forwarded to the national register with some delay (hence the shorter follow-up for this endpoint). Mortality is reported centrally with cause of death (both underlying and ‘mentioned’ i.e. a condition that contributed to but did not cause the death) on the death certificate coded routinely using the World Health Organization’s International Classification of Diseases (ICD) codes, version 9 until 2000 and version 10 in subsequent years. For this follow-up the outcomes of interest were death (all cause), and deaths from ischemic heart disease (ICD-9 410-414; ICD-10 I20-I25), any cardiac diagnosis (ICD-9 codes 393-398, 410-414, 415-417, 420-429; ICD-10 I05-I09, I20-I25, I26-I28, I30-I52), stroke (ICD 9: 430-438, ICD-10:  I160-168),  any cancer (ICD-9 140-209, ICD-10 C00-C97), breast cancer (ICD-9 174; ICD-10 C50) and endometrial cancer (ICD-9 182; ICD-10 C54.1).  Incidence of cancer in this analysis, for any cancer, breast cancer and endometrial cancer, was taken from cancer notifications with the same ICD codes as those in the mortality analysis. 
Analysis




 There were 418 deaths among the 1017 women recruited to ESPRIT, 214 among the 513 in the treatment arm, 204 among the 504 in the placebo arm (Table 1). The overall HR for all cause mortality was 1.07 (95% CI: 0.88-1.29) (Table 2).  Heart disease was recorded as the underlying cause for 177 (42.3%) of the 418 deaths and as either the underlying cause or as a condition mentioned elsewhere on the death certificate (‘any mention’ in the tables) in 269 (64.4%) deaths. Estimates of hazard ratios (Table 2) for all women showed no significant detrimental or protective effect of treatment, although the ratios were above unity for heart disease and stroke.  When stratified by age, women recruited at age 50-59 years had lower hazard ratios (except for IHD) than those aged 60-69 years at recruitment although none of the differences between age groups was  significant (p>0.05). 
There were 5 deaths attributed to breast cancer (1 in the active treatment group, 4 in placebo) as the underlying cause. There were 7 women with ‘any mention’ of breast cancer on the death certificate, 3 in the active arm, and 4 in placebo. Endometrial cancer was not reported on any death certificate, either as an underlying or ‘mentioned’ cause. Although not an outcome specified a priori, three death certificates with codes for ovarian cancer (ICD-9 183.0; ICD-10 C56) were noted, all in the active arm (p=0.25, Fisher’s exact test)

2) Cancer incidence
There were 149 incident malignant cancers among 142 women, plus 13 in situ or benign tumours (none breast or genital; excluded from the analysis). The HR was close to unity for any cancer (all types) among all 1017 women, with lower HRs for those under 60 years of age at recruitment (Table 2). There were 22 incident cases of breast cancer, 7 in the treatment group and 15 in placebo. HRs for breast cancer were below unity for the treatment arm overall and for both younger and older women when examined separately, with women aged 50-59 years having the smallest risk estimate (0.33). For the group as a whole, the (two sided) probability of an HR of 0.47 or smaller, under the null hypothesis, was 0.097, having adjusted for age at risk.




This follow-up of ESPRIT was primarily to investigate whether any harm had been done by using unopposed estrogen in women with an intact uterus. No harm has been demonstrated. Although during the trial more than half of the women in the active arm with a uterus reported bleeding, no woman was diagnosed with endometrial cancer during active follow-up [1]. The unexpected observation of more ovarian cancer in the treatment arm is consistent with chance and has not been reported in other trials
As in the initial report, there was no significant difference between women in the active and treatment arms on any of the outcomes considered. In the current analysis, the lowest HR (0.47, suggesting a protective effect of active treatment) was for incident breast cancer, with the likelihood of such an effect arising by chance being <0.10. For all the outcomes (except IHD as underlying cause) considered in this extended ESPRIT follow-up, the HR for women aged 50-59 years at recruitment was lower than for  older women. 
Strengths and Limitations:
Since all of the women were flagged for death and cancers at the NHS Central registries, we should have captured all such events occurring in the trial participants; in effect there was no loss to follow-up.  Although our study had limited statistical power for some of the endpoints included in the analysis it had 80% power to detect a 20% decrease in all cause mortality. The observation on endometrial cancer was based on only 373 women with an intact uterus in the active arm and 399 in the placebo. We did not obtain during the observational extended follow-up of the original trial participants data on non-fatal clinical events other than cancer incidence. It cannot, therefore, add to reports of other outcomes (e.g. gall bladder disease, venous thrombo-embolism, non-fatal stroke) that have been associated with unopposed estrogen elsewhere [2].   Neither could we assess whether over time unopposed oestrogen affects the risk of non-fatal myocardial re-infarction.  Data were not available about use of hormone replacement therapy after the formal trial ended.  Some women may have subsequently used these products although the number is probably small due to the widespread publicity that occurred in the Summer of 2002 concerning the premature cessation of the oestrogen plus progestin trial of the Women’s Health Initiative (6), leading to regulatory advice in the UK to avoid long-term use [8]The absence of adverse effect on the endometrium in this study is likely to be, in large part, a reflection of the management of bleeding during and at the end of the active intervention [1]. Eight women found to have atypical hyperplasia during the trial were immediately started on a 3 month course of cyclical medroxyprogesterone acetate: all endometrial abnormalities resolved and none of the women required a hysterectomy during the 2 years of the trial.  The conclusion of no adverse effect, therefore, should not be generalized to situations without such active management. The unexpected observation of more ovarian cancer in the treatment arm is consistent with chance and has not been reported in other trials.

Interpretation
In its most recent follow-up, the WHI E-A found a significantly reduced HR for breast cancer in those randomized to unopposed estrogen (0.77: 95% CI 0.62-0.95) [7]. The size of the protective effect was much the same at 10.7 years as at 7.1 years but with more events increasing the trial’s power, a stronger conclusion of benefit was possible. Younger women in the active treatment arm of the WHI E-A study had a similar reduction in risk of breast cancer as older women. In a recently reported trial from Denmark, 192 women aged 45-52 years who had undergone hysterectomy were randomly assigned to take taking unopposed estrogen (N=95) or to no treatment (N=97) and followed up for death, cardiovascular disease and cancer for 16 years [9]. Those on unopposed estrogen as their active treatment were reported to have an HR (0.63: 95% CI 0.23-1.78) for breast cancer similar to that in the WHI E-A trial. The lower breast cancer incidence in the women in ESPRIT is consistent with these earlier reports.
The WHI E-A also showed greater benefit of active treatment in younger than in older women at 10.7 years of follow-up. Rates were lower for incident CHD, MI and death (all causes) [7]. The incident data for CHD and MI is not comparable with ESPRIT, where all the women had been recruited post-MI, but the lower HR for death from all causes was seen in younger women in both studies. 
The WHI E-A found an increased risk of stroke at 7.1 years [5], but by 10.7 years there was no significant increase in the active intervention group, overall or in any age specific group [7]. In ESPRIT, clinical reports of stroke were somewhat higher in the intervention arm at the end of 2 years (risk ratio 1.64 95%CI 0.60-4.47) [1]. Non-fatal strokes were not identified in the follow-up reported here but there was only a small excess of deaths in which stroke appeared as an underlying or ‘mentioned’ cause among those assigned to estrogen, again consistent with the findings from the larger US trial.
Conclusion.
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Ischemic heart disease (IHD)	23	13.8	14	10.5	66	19.1	58	15.7	89	17.3	72	14.3
Any heart disease	24	14.4	16	11.9	73	21.1	64	17.3	97	18.9	80	15.9
Stroke	2	1.2	2	1.5	13	3.8	11	3.0	15	2.9	13	2.6
Cancer – all sites	10	6.0	11	8.2	28	8.1	28	7.6	38	7.4	39	7.7
Any mention												
Ischemic heart disease (IHD)	31	18.6	20	14.9	95	27.5	89	24.1	126	24.6	109	21.6
Any heart disease	32	19.2	27	20.2	109	31.5	101	27.3	141	27.5	128	25.4
Stroke	3	1.8	5	3.7	22	6.4	16	4.3	25	4.9	21	4.2









Table 2:  Hazard ratio (active/placebo) by age at recruitment (adjusted for age at risk)
Age
Outcome	50-59	60-69	All Ages




Ischemic heart disease (IHD)	1.23	0.63-2.41	1.23	0.87-1.76	1.24	0.91-1.70
Any heart disease	1.14	0.60-2.16	1.24	0.89-1.73	1.22	0.91-1.64
Stroke	0.73	0.10-5.21	1.29	0.58-2.88	1.18	0.56-2.49
Cancer – all sites	0.71	0.30-1.67	1.09	0.65-1.84	0.91	0.62-1.52
Any mention						
Ischemic heart disease (IHD)	1.19	0.67-2.08	1.16	0.87-1.54	1.18	0.91-1.52
Any heart disease	0.91	0.54-1.51	1.18	0.90-1.54	1.12	0.88-1.42
Stroke	0.45	0.11-1.89	1.51	0.79-2.88	1.22	0.68-2.18
Cancer – all sites	0.91	0.41-2.04	1.06	0.65-1.71	1.03	0.68-1.55
Cancer Incidence						
All sites	0.70	0.35-1.40	1.08	0.74-1.57	0.97	0.70-1.35
Breast cancer	0.33	0.06-1.68	0.54	0.19-1.59	0.47	0.19-1.15
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